Subject: Specialised Services Circular (SSC 2598)
Sent on behalf of: Chair of the SW Specialised Service Circular Group

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
2598	**Siltuximab for idiopathic Multicentric Castleman Disease (iMCD) NHS England Clinical Commissioning Policy: 2124**	Adults - All SW Acute Providers Paediatrics - University Hospital Bristol and Weston NHS FT

Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? No

For all other South West region trusts this is for information only.

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: england.speccomm-southwest@nhs.net

Specialised Commissioning South West
NHS England
360 Bristol
Marlborough Street
Bristol
BS1 3NX
Email: england.speccomm-southwest@nhs.net

28 December 2023

All Chief Executives

All Medical Directors

All Chief Pharmacists

Dear Colleagues,

Siltuximab for idiopathic Multicentric Castleman Disease (iMCD) NHS England Clinical Commissioning Policy: 2124

I am writing to advise you regarding the funding position on the recently published NHS England Clinical Commissioning Policy (CCP) for idiopathic Multicentric Castleman Disease (iMCD).

The CCP can be found at: https://www.england.nhs.uk/publication/clinical-commissioning-policy-siltuximab/

Siltuximab will be routinely commissioned from 10 November 2023 in line with these recommendations.

The decision to initiate treatment with siltuximab should be by physicians with significant experience in the treatment of iMCD. A National Advisory Panel has been set up to facilitate discussion regarding all types of Castleman Disease diagnosis and management, the address to submit patients for discussion is: https://cdnuk.e-dendrite.com/. Enquiries can be sent via email to gst-tr.CastlemanService@nhs.net. For further information see the website: https://www.cdnetwork.uk/

In addition, NHS England will commission siltuximab in children where siltuximab is used in accordance with the NHS England policy 'Commissioning medicines for children in specialised services' as regards post-pubescent patients. In this setting the use of siltuximab must be discussed at a multi-disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area. Separate Blueteq registration forms for registration of adults and post-pubescent children have been made available. It should also be noted that siltuximab should be used within the Trusts governance framework as siltuximab is not licensed for use in children.

In addition:

- Trusts must ensure that they are purchasing siltuximab at the agreed patient access scheme (PAS) discounted price. This discounted price will be applied automatically at point of invoice and applies to all indications.
- Trusts must ensure that only invoices for the drug procurement costs of siltuximab in this indication are invoiced to NHSE and that they are also submitting complete and accurate information via the minimum dataset (MDS). All other on cost are in block arrangements.
- In line with the terms and conditions included in the NHS Standard Contract and as per the agreement that Cancer Services are commissioned with Trusts, Schedule 6a Reporting Requirements for drugs will apply. Payment of Trust invoices will be contingent on the completion of the MDS record and this information being made available in a timely way.
- Patients must be registered via Blueteq and meet the clinical criteria on the registration form. This letter gives the required one month's notice as per Schedule 2 Part G (Other Local Agreements, Policies and Procedures) of your Specialised Services contract for prior approval for this treatment/indication. From one month of the date specified above, NHS England will only reimburse these treatments for patients that have been confirmed as meeting the eligibility criteria via the formal Prior Approval Scheme (i.e., Blueteq). You may wish to use the prior approval mechanism earlier than this to expedite access to this drug.
- **Payment of Trust invoices will be contingent on Blueteq registration and the full Minimum Data Set (MDS) record applicable to the drug being completed and this information being made available in a timely way. Please note there are different Blueteq registration forms for adults and children.**

- Trusts must ensure that local governance aspects (e.g., technical issues, education & training, patient information) have been identified and addressed for all staff groups (as appropriate), in order to permit the safe delivery of this therapy.

Trusts should refer to the CAP portal for further information on the PAS price. The CAP portal is available at https://nhsengland.sharefile.eu/Authentication/Login
I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent adoption of the policy nationally.

Yours sincerely,

Luke Culverwell
Deputy Director of Specialised Commissioning

Tracey Williams
Principal Pharmacist